Endocannabinoid-metabolizing enzymes in tumors helped colon cancer evade the immune system in mice

What the researchers found

CYP4X1 and sEH enzymes metabolize endocannabinoids to produce 14,15-EET-EA, which acts on GPR119 receptors in cancer-associated fibroblasts. This upregulates PD-L1, CXCL12, and TGF-beta, promoting regulatory T cell infiltration and impairing CD8+ T cell function. Blocking the CYP4X1/sEH-GPR119 axis enhanced anti-PD-1 immunotherapy efficacy in mice.

Why it matters

Immunotherapy has transformed cancer treatment but only works in a fraction of patients. This research identifies a specific endocannabinoid metabolism pathway that tumors exploit to evade immune attack, offering a potential new drug target to make immunotherapy more effective.

The numbers in context

Key metabolite identified: 14,15-EET-EA. Receptor: GPR119. Signaling: Gs/beta-arrestin 2 axis. Downstream effects: upregulation of PD-L1, CXCL12, and TGF-beta in cancer-associated fibroblasts. CYP4X1 and sEH levels jointly predicted prognosis in human colon cancer.

How the study worked

Preclinical study using mouse colon cancer models and human colon cancer tissue analysis. Investigated the CYP4X1/sEH pathway for endocannabinoid metabolism, identified the 14,15-EET-EA metabolite and its receptor GPR119, and tested pathway inhibition combined with anti-PD-1 therapy.

What this study cannot tell us

Mouse models do not always translate to human outcomes. The pathway was studied primarily in colon cancer; relevance to other cancers is unknown. No clinical trials yet. Complexity of the signaling pathway may make therapeutic targeting challenging.

How to read the evidence

Rigorous preclinical work with mechanistic detail and human tissue validation, but all therapeutic findings are from mouse models with no clinical data.

When this study was published

2026 publication

The bigger picture

The endocannabinoid system is increasingly recognized as playing roles far beyond mood and pain. This study reveals it as a key player in how tumors manipulate their microenvironment to survive, opening up entirely new strategies for combination immunotherapy.

Questions still open

• Would drugs targeting CYP4X1/sEH improve immunotherapy outcomes in human clinical trials? Does exogenous cannabis use affect this pathway in cancer patients? Is this mechanism active in cancers other than colon cancer?

Common questions

Read the original research

CYP4X1/sEH-Dependent Endocannabinoid Metabolism Drives Fibroblast-Mediated Immunosuppression to Limit Immunotherapy in Colon Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e07695

Citation

Mo, Min; Chen, Xuewei; Liu, Yanzhuo; Wang, Chenlong; Chen, Xuehan; Zhang, Nan; He, Nan; Li, Ying; Wang, Jingyi; Chen, Honglei; Yang, Jing. (2026). CYP4X1/sEH-Dependent Endocannabinoid Metabolism Drives Fibroblast-Mediated Immunosuppression to Limit Immunotherapy in Colon Cancer.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(5), e07695. https://doi.org/10.1002/advs.202507695

Explore the wider topic

• CBD Oil Quality Guide: How to Avoid Snake Oil
• Anxiety After Quitting Weed: When to Consider Medication
• Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
• Cannabis for Chronic Pain: What the Research Actually Supports
• Cannabis and Epilepsy: The Epidiolex Story and What It Means
• Does CBD Actually Work for Anxiety? What the Evidence Shows
• Does CBD Help with Weed Withdrawal? What Studies Show
• CBD vs THC: The Differences That Actually Matter
• The Proven Medical Benefits of Cannabis: What Research Supports
• Quitting Weed Before Surgery
• Weed and Medications: What Changes When You Quit
• Quitting Weed During Pregnancy: What You Need to Know
• Quitting Weed While Pregnant: What You Need to Know
• Cannabis and Older Adults: Risks Seniors Should Know
• Cannabis and Breastfeeding: THC in Breast Milk